Loading Events

Opus Genetics Virtual KOL Event on Clinical Results of OPGx-LCA5 to Treat LCA5-Associated Inherited Retinal Disease

Banners - 2024-11-08T093725.902
DATE: December 11, 2024
TIME: 4:00 PM EST
LOCATION: Virtual

About The Event

Join Opus Genetics for a virtual KOL event featuring Jean Bennett, MD, PhD and Tomas Aleman, MD from the University of Pennsylvania, along with Christine Kay, MD, and Arshad Khanani, MD, MA, FASRS, who will discuss the new 6-month efficacy and safety data of OPGx-LCA5, an adeno-associated virus (AAV)-based gene therapy in Phase 1/2 development for LCA5-associated inherited retinal disease (IRD).

The event will focus on OPGx-LCA5 clinical data from the study and will dive into the key efficacy assessments in detail. It will also highlight the current unmet need in LCA5-associated inherited retinal disease, next steps in the development program, and the potential of Opus’ therapeutic approach. Opus Genetics is a clinical-stage ophthalmic biotechnology company developing important new therapies for the treatment of IRDs and other ophthalmic disorders.

A live question and answer session will follow the formal presentation.